Partial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with HER2 Amplification and R157W Mutation After Anti-HER2 Treatment: A Case Report and Literature Review
Yanchun Qu,1– 3,* Yufeng Liu,3,* Kailin Ding,3 Yong Li,1,2 Xiaoyu Hong,4 Haibo Zhang1,2 1Department of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China; 2Department of Oncology, Guangdong Provincial Hospit...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-03-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/partial-response-to-pyrotinib-plus-capecitabine-in-an-advanced-breast--peer-reviewed-article-OTT |
id |
doaj-f4041c12d8a24f1ba3b17d4bafcc39d2 |
---|---|
record_format |
Article |
spelling |
doaj-f4041c12d8a24f1ba3b17d4bafcc39d22021-03-04T19:00:37ZengDove Medical PressOncoTargets and Therapy1178-69302021-03-01Volume 141581158862677Partial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with HER2 Amplification and R157W Mutation After Anti-HER2 Treatment: A Case Report and Literature ReviewQu YLiu YDing KLi YHong XZhang HYanchun Qu,1– 3,* Yufeng Liu,3,* Kailin Ding,3 Yong Li,1,2 Xiaoyu Hong,4 Haibo Zhang1,2 1Department of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China; 2Department of Oncology, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, People’s Republic of China; 3The Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China; 4Nanjing Geneseeq Technology Inc, Nanjing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Haibo ZhangDepartment of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 111 Dade Road, Yuexiu District, Guangzhou, 510120, People’s Republic of ChinaTel +86-020-81887233Email haibozh@gzucm.edu.cnAbstract: Human epidermal growth factor receptor2 (HER2) overexpression/amplification is associated with high malignancy, rapid disease progression and poor overall survival in breast cancer. The application of anti-HER2 drugs has greatly improved the survival of patients with HER2-positive breast cancer, but drug resistance issues affect the long-term efficacy. The HER2 mutation is considered to be one of the reasons for resistance to anti-HER2 therapy, and there is currently no standard treatment. We report for the first time the detection of HER2 amplification with R157W mutation by second-generation sequencing (NGS) in a 57-year-old hormone receptor-negative, HER2-positive woman with advanced breast cancer who was resistant to multi-line anti-HER2 therapies. She subsequently received pyrotinib combined with capecitabine treatment and achieved partial response. The small-molecule pan-HER family irreversible inhibitor pyrotinib combined with capecitabine has shown a promising effect in the treatment of HER2 mutation-induced resistance, but the molecular mechanism and efficacy need to be further verified.Keywords: breast cancer, HER2 amplification, HER2 R157W mutation, pyrotinib plus capecitabine, anti-HER2 treatmenthttps://www.dovepress.com/partial-response-to-pyrotinib-plus-capecitabine-in-an-advanced-breast--peer-reviewed-article-OTTbreast cancerher2 amplificationher2 r157w mutationpyrotinib plus capecitabineanti-her2 treatment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Qu Y Liu Y Ding K Li Y Hong X Zhang H |
spellingShingle |
Qu Y Liu Y Ding K Li Y Hong X Zhang H Partial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with HER2 Amplification and R157W Mutation After Anti-HER2 Treatment: A Case Report and Literature Review OncoTargets and Therapy breast cancer her2 amplification her2 r157w mutation pyrotinib plus capecitabine anti-her2 treatment |
author_facet |
Qu Y Liu Y Ding K Li Y Hong X Zhang H |
author_sort |
Qu Y |
title |
Partial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with HER2 Amplification and R157W Mutation After Anti-HER2 Treatment: A Case Report and Literature Review |
title_short |
Partial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with HER2 Amplification and R157W Mutation After Anti-HER2 Treatment: A Case Report and Literature Review |
title_full |
Partial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with HER2 Amplification and R157W Mutation After Anti-HER2 Treatment: A Case Report and Literature Review |
title_fullStr |
Partial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with HER2 Amplification and R157W Mutation After Anti-HER2 Treatment: A Case Report and Literature Review |
title_full_unstemmed |
Partial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with HER2 Amplification and R157W Mutation After Anti-HER2 Treatment: A Case Report and Literature Review |
title_sort |
partial response to pyrotinib plus capecitabine in an advanced breast cancer patient with her2 amplification and r157w mutation after anti-her2 treatment: a case report and literature review |
publisher |
Dove Medical Press |
series |
OncoTargets and Therapy |
issn |
1178-6930 |
publishDate |
2021-03-01 |
description |
Yanchun Qu,1– 3,* Yufeng Liu,3,* Kailin Ding,3 Yong Li,1,2 Xiaoyu Hong,4 Haibo Zhang1,2 1Department of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China; 2Department of Oncology, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, People’s Republic of China; 3The Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China; 4Nanjing Geneseeq Technology Inc, Nanjing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Haibo ZhangDepartment of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 111 Dade Road, Yuexiu District, Guangzhou, 510120, People’s Republic of ChinaTel +86-020-81887233Email haibozh@gzucm.edu.cnAbstract: Human epidermal growth factor receptor2 (HER2) overexpression/amplification is associated with high malignancy, rapid disease progression and poor overall survival in breast cancer. The application of anti-HER2 drugs has greatly improved the survival of patients with HER2-positive breast cancer, but drug resistance issues affect the long-term efficacy. The HER2 mutation is considered to be one of the reasons for resistance to anti-HER2 therapy, and there is currently no standard treatment. We report for the first time the detection of HER2 amplification with R157W mutation by second-generation sequencing (NGS) in a 57-year-old hormone receptor-negative, HER2-positive woman with advanced breast cancer who was resistant to multi-line anti-HER2 therapies. She subsequently received pyrotinib combined with capecitabine treatment and achieved partial response. The small-molecule pan-HER family irreversible inhibitor pyrotinib combined with capecitabine has shown a promising effect in the treatment of HER2 mutation-induced resistance, but the molecular mechanism and efficacy need to be further verified.Keywords: breast cancer, HER2 amplification, HER2 R157W mutation, pyrotinib plus capecitabine, anti-HER2 treatment |
topic |
breast cancer her2 amplification her2 r157w mutation pyrotinib plus capecitabine anti-her2 treatment |
url |
https://www.dovepress.com/partial-response-to-pyrotinib-plus-capecitabine-in-an-advanced-breast--peer-reviewed-article-OTT |
work_keys_str_mv |
AT quy partialresponsetopyrotinibpluscapecitabineinanadvancedbreastcancerpatientwithher2amplificationandr157wmutationafterantiher2treatmentacasereportandliteraturereview AT liuy partialresponsetopyrotinibpluscapecitabineinanadvancedbreastcancerpatientwithher2amplificationandr157wmutationafterantiher2treatmentacasereportandliteraturereview AT dingk partialresponsetopyrotinibpluscapecitabineinanadvancedbreastcancerpatientwithher2amplificationandr157wmutationafterantiher2treatmentacasereportandliteraturereview AT liy partialresponsetopyrotinibpluscapecitabineinanadvancedbreastcancerpatientwithher2amplificationandr157wmutationafterantiher2treatmentacasereportandliteraturereview AT hongx partialresponsetopyrotinibpluscapecitabineinanadvancedbreastcancerpatientwithher2amplificationandr157wmutationafterantiher2treatmentacasereportandliteraturereview AT zhangh partialresponsetopyrotinibpluscapecitabineinanadvancedbreastcancerpatientwithher2amplificationandr157wmutationafterantiher2treatmentacasereportandliteraturereview |
_version_ |
1724231762174803968 |